Rocket Pharmaceuticals Stock Performance
| RCKT Stock | USD 3.54 0.01 0.28% |
The company holds a Beta of 2.84, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Rocket Pharmaceuticals will likely underperform. Rocket Pharmaceuticals right now holds a risk of 4.92%. Please check Rocket Pharmaceuticals value at risk, and the relationship between the jensen alpha and skewness , to decide if Rocket Pharmaceuticals will be following its historical price patterns.
Risk-Adjusted Performance
Soft
Weak | Strong |
Over the last 90 days Rocket Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable forward-looking signals, Rocket Pharmaceuticals is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors. ...more
Actual Historical Performance (%)
One Day Return (0.28) | Five Day Return 0.85 | Year To Date Return 2.31 | Ten Year Return (90.98) | All Time Return (85.25) |
Last Split Factor 1:4 | Dividend Date 2018-01-05 | Last Split Date 2018-01-05 |
1 | Why Rocket Pharmaceuticals Inc. stock remains on buy lists - Weekly Trading Summary Real-Time Volume Analysis - newser.com | 10/24/2025 |
2 | Acquisition by Wilson Martin of 100000 shares of Rocket Pharmaceuticals subject to Rule 16b-3 | 11/03/2025 |
3 | Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress | 11/06/2025 |
4 | Can Rocket Pharmaceuticals Inc. stock withstand economic slowdown - Gold Moves Low Risk High Reward Trade Ideas - newser.com | 11/11/2025 |
5 | Can Rocket Pharmaceuticals Inc. stock deliver strong Q4 earnings - July 2025 Trends Real-Time Market Sentiment Alerts - newser.com | 11/14/2025 |
6 | Disposition of 1646 shares by Wilson Martin of Rocket Pharmaceuticals at 2.983 subject to Rule 16b-3 | 11/18/2025 |
7 | Rocket Pharmaceuticals, Inc. Receives Average Rating of Hold from Brokerages | 11/24/2025 |
8 | Rocket Pharmaceuticals Nasdaq Index Drives Rare-Disease Research | 12/09/2025 |
9 | Rocket Pharmaceuticals Stock Target Reduced Following Q3 2025 Update on Cash Position | 12/16/2025 |
10 | Acquisition by Bjork Elisabeth of 10000 shares of Rocket Pharmaceuticals at 3.44 subject to Rule 16b-3 | 01/02/2026 |
11 | Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference | 01/05/2026 |
| Begin Period Cash Flow | 57.3 M | |
| Total Cashflows From Investing Activities | 131.7 M |
Rocket Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 367.00 in Rocket Pharmaceuticals on October 9, 2025 and sell it today you would lose (13.00) from holding Rocket Pharmaceuticals or give up 3.54% of portfolio value over 90 days. Rocket Pharmaceuticals is currently generating 0.0544% in daily expected returns and assumes 4.9231% risk (volatility on return distribution) over the 90 days horizon. In different words, 44% of stocks are less volatile than Rocket, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Rocket Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Rocket Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Rocket Pharmaceuticals, and traders can use it to determine the average amount a Rocket Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.011
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | RCKT | Huge Risk |
| Negative Returns |
Based on monthly moving average Rocket Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Rocket Pharmaceuticals by adding Rocket Pharmaceuticals to a well-diversified portfolio.
Rocket Pharmaceuticals Fundamentals Growth
Rocket Stock prices reflect investors' perceptions of the future prospects and financial health of Rocket Pharmaceuticals, and Rocket Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Rocket Stock performance.
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.41 | ||||
| Current Valuation | 184.85 M | ||||
| Shares Outstanding | 108.22 M | ||||
| Price To Book | 1.23 X | ||||
| EBITDA | (247.49 M) | ||||
| Net Income | (258.75 M) | ||||
| Cash And Equivalents | 321.37 M | ||||
| Cash Per Share | 4.87 X | ||||
| Total Debt | 25.5 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 13.41 X | ||||
| Book Value Per Share | 2.90 X | ||||
| Cash Flow From Operations | (209.72 M) | ||||
| Earnings Per Share | (2.25) X | ||||
| Market Capitalization | 383.11 M | ||||
| Total Asset | 527.7 M | ||||
| Retained Earnings | (1.22 B) | ||||
| Working Capital | 337.5 M | ||||
About Rocket Pharmaceuticals Performance
Assessing Rocket Pharmaceuticals' fundamental ratios provides investors with valuable insights into Rocket Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Rocket Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.50) | (0.53) | |
| Return On Capital Employed | (0.65) | (0.68) | |
| Return On Assets | (0.44) | (0.46) | |
| Return On Equity | (0.64) | (0.67) |
Things to note about Rocket Pharmaceuticals performance evaluation
Checking the ongoing alerts about Rocket Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Rocket Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Rocket Pharmaceuticals had very high historical volatility over the last 90 days | |
| Net Loss for the year was (258.75 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Rocket Pharmaceuticals currently holds about 321.37 M in cash with (209.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.87, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Rocket Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 90.0% of the company shares are owned by institutional investors |
- Analyzing Rocket Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Rocket Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Rocket Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Rocket Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Rocket Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Rocket Pharmaceuticals' stock. These opinions can provide insight into Rocket Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Rocket Stock Analysis
When running Rocket Pharmaceuticals' price analysis, check to measure Rocket Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rocket Pharmaceuticals is operating at the current time. Most of Rocket Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Rocket Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rocket Pharmaceuticals' price. Additionally, you may evaluate how the addition of Rocket Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.